Cyclin-dependent kinase inhibitor seliciclib shows<i>in vitro</i>activity in diffuse large B-cell lymphomas
Katia Lacrima(Consiglio per la ricerca in agricoltura e l’analisi dell’economia agraria), Francesco Bertoni(Ente Ospedaliero Cantonale), Andrea Rinaldi(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Gianluca Gaïdano(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Sara Vignati(Institute of Oncology Research), Carlo V. Catapano(Institute of Oncology Research), Vittoria Martin(University of Insubria), Maria Grazia Tibiletti(University of Insubria)
Cited by 22
Related Papers
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database
|Genetics in Medicine|2019|666
The coding genome of splenic marginal zone lymphoma: activation of <i>NOTCH2</i> and other pathways regulating marginal zone development
|The Journal of Experimental Medicine|2012|378